drugset

drugset / Trial / NCT02254031

Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer

NCT02254031 ↗

Phase 1 Terminated 8 enrolled Boehringer Ingelheim

NaSingle-groupOpen-labelTreatment

Summary

maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine

Timeline

Start: 2003-07-01
Primary completion: 2005-01-01
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	bivatuzumab mertansine	Unknown	—	Intravenous

Indications